Cited by 160Urinary Tract Infections ManagementBacterial Identification and Susceptibility TestingGenomics and Phylogenetic Studies

Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract

Open access
Burnham, Philip, Dadhania, Darshana, Heyang, Michael, Chen, Fanny, Westblade, Lars F., Suthanthiran, Manikkam, Lee, John Richard, De Vlaminck, Iwijn·2018·Nature Communications

Published version of a preprint

Abstract

Urinary tract infections are one of the most common infections in humans. Here we tested the utility of urinary cell-free DNA (cfDNA) to comprehensively monitor host and pathogen dynamics in bacterial and viral urinary tract infections. We isolated cfDNA from 141 urine samples from a cohort of 82 kidney transplant recipients and performed next-generation sequencing. We found that urinary cfDNA is highly informative about bacterial and viral composition of the microbiome, antimicrobial susceptibility, bacterial growth dynamics, kidney allograft injury, and host response to infection. These different layers of information are accessible from a single assay and individually agree with corresponding clinical tests based on quantitative PCR, conventional bacterial culture, and urinalysis. In addition, cfDNA reveals the frequent occurrence of pathologies that remain undiagnosed with conventional diagnostic protocols. Our work identifies urinary cfDNA as a highly versatile analyte to monitor infections of the urinary tract.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04745-0

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Blood-based microbial DNA can be clinically informative in cancer, including cancers with blood-barrier or lymphatic disruptions.

    “There is mounting evidence that blood-based microbial DNA (hereafter “mbDNA”) can be clinically informative in cancer39–44, including those featuring blood-barrier or lymphatic disruptions (e.g. COAD)39”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 64 · Cited by 160

Authors
Burnham, P., Dadhania, D., Heyang, M., Chen, F., Westblade, L. F., Suthanthiran, M., Lee, J. R., & De Vlaminck, I.
Affiliations
  • Cornell University (US)
  • NewYork–Presbyterian Hospital (US)
  • Weill Cornell Medicine (US)
Corresponding author
Lee, John Richard
Venue
Nature Communications
Published
2018-06-20
Volume
9
Issue
1
Pages
2412-2412
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2807732072
Cited by
160
References
64
Citations by year
2026: 7 · 2025: 17 · 2024: 23 · 2023: 12 · 2022: 24 · 2021: 27 · 2020: 30 · 2019: 15 · 2018: 5
FWCI
15.23
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science Foundation (1144153)
  • Noyce Foundation
  • National Institutes of Health (1dp2ai138242-01)
  • National Institute of Allergy and Infectious Diseases (DP2 AI138242, R21AI133331, K23AI124464, R37AI051652, R21AI124237)
Topics
  • Health Sciences › Medicine › Epidemiology › Urinary Tract Infections Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Bacterial Identification and Susceptibility Testing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
Keywords
urinary cell-free DNA, urinary tract infection, kidney transplant recipients, urinary microbiome, antimicrobial susceptibility, bacterial growth dynamics, host response to infection, infection monitoring, liquid biopsy
MeSH terms
Cell-Free Nucleic Acids, DNA, Bacterial, DNA, Viral, Female, Humans, Male, Urinary Tract, Urinary Tract Infections, Cohort Studies, Biomarkers, Sequence Analysis, DNA, Host-Pathogen Interactions, High-Throughput Nucleotide Sequencing, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review